Pedro P Lopez-Casas

7PUBLICATIONS
68CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 14, 2024
A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial.

Francesca Sarno, Jair Tenorio, Sofia Perea

|Jun 02, 2021
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.

Rebeca Lozano, David Lorente, Isabel M Aragon

|Oct 15, 2020
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors.

Iván Márquez-Rodas, Federico Longo, Maria E Rodriguez-Ruiz

|Oct 15, 2020
Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma.

Anusha Kalbasi, Mito Tariveranmoshabad, Kevin Hakimi

|Jun 06, 2020
Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor Cells.

Spas Dimitrov-Markov, Javier Perales-Patón, Bruno Bockorny

|Mar 13, 2020
OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models.

Myriam Fabre, Cristina Ferrer, Saioa Domínguez-Hormaetxe

Pageof 2

Frequent Collaborators

2 joint publications

Marisol Quintero

2 joint publications

Ana Dopazo

1 joint publications

Herwig P Moll

1 joint publications

Klemens Pranz